Skip to main content
Cancer Medicine logoLink to Cancer Medicine
. 2021 Mar 5;10(7):2523–2525. doi: 10.1002/cam4.3701

Corrigendum

PMCID: PMC7982626  PMID: 33749167

In the article by Ying Cheng et al., the authors have noticed that there is a mistake in Figure 1B (hazard ratio data) due to copying error and in Table 2 (SCC part) due to miscalculation error.

TABLE 2.

Common adverse events (≥10%) in ACC and SCC patients

Adverse events All grades ≥Grade 3 All grades ≥Grade 3
SCC Anlotinib, n = 53 Placebo, n = 33
Hypertension 34 (64.15%) 10 (18.87%) 7 (21.21%) 0 (0%)
Fatigue 25 (47.17%) 1 (1.89%) 5 (15.15%) 0 (0%)
TSH elevation 21 (39.62%) 0 (0%) 6 (18.18%) 0 (0%)
Anorexia 21 (39.62%) 0 (0%) 3 (9.09%) 0 (0%)
HFSR 19 (35.85%) 1 (1.89%) 3 (9.09%) 0 (0%)
Cough 16 (30.19%) 0 (0%) 4 (12.12%) 2 (6.06%)
TC elevation 15 (28.30%) 1 (1.89%) 3 (9.09%) 0 (0%)
Triglyceride elevation 15 (28.30%) 0 (0%) 4 (12.12%) 1 (3.03%)
Sinus arrhythmia 15 (28.30%) 0 (0%) 3 (9.09%) 0 (0%)
Diarrhea 15 (28.30%) 0 (0%) 2 (6.06%) 0 (0%)
Hemoptysis 14 (26.42%) 5 (9.43%) 3 (9.09%) 1 (3.03%)
Proteinuria 14 (26.42%) 2 (3.77%) 7 (21.21%) 0 (0%)
Pharyngalgia 14 (26.42%) 1 (1.89%) 8 (24.24%) 0 (0%)
Hoarse 14 (26.42%) 1 (1.89%) 2 (6.06%) 0 (0%)
Hyperglycemia 13 (24.53%) 0 (0%) 0 (0%) 0 (0%)
Hyperbilirubinemia 13 (24.53%) 0 (0%) 0 (0%) 0 (0%)
Prolongation of the QT interval 11 (20.75%) 3 (5.66%) 0 (0%) 0 (0%)
Hypophosphatemia 11 (20.75%) 1 (1.89%) 4 (12.12%) 0 (0%)
Oral mucositis 11 (20.75%) 1 (1.89%) 1 (3.03%) 0 (0%)
Hyponatremia 10 (18.87%) 6 (11.32%) 1 (3.03%) 0 (0%)
GT elevation 10 (18.87%) 2 (3.77%) 1 (3.03%) 0 (0%)
Weight loss 10 (18.87%) 0 (0%) 1 (3.03%) 0 (0%)
LYM reduction 9 (16.98%) 2 (3.77%) 5 (15.15%) 1 (3.03%)
Nausea 9 (16.98%) 0 (0%) 7 (21.21%) 0 (0%)
LDL elevation 8 (15.09%) 0 (0%) 9 (27.27%) 0 (0%)
Vomiting 8 (15.09%) 0 (0%) 6 (18.18%) 0 (0%)
Rash 8 (15.09%) 0 (0%) 3 (9.09%) 0 (0%)
Hypothyroidism 8 (15.09%) 0 (0%) 2 (6.06%) 0 (0%)
Urine occult blood 7 (13.21%) 0 (0%) 3 (9.09%) 0 (0%)
Paresthesia 7 (13.21%) 0 (0%) 2 (6.06%) 0 (0%)
Dyspnea 7 (13.21%) 0 (0%) 1 (3.03%) 0 (0%)
Productive cough 6 (11.32%) 0 (0%) 0 (0%) 0 (0%)

The authors have mistakenly put the incorrect values in Figure 1B (hazard ratio data) and also the relevant values are revised in the section under Discussion in text part. The correct version of Figure 1B is displayed below:

graphic file with name CAM4-10-2523-g001.jpg

Revised relevant values in the text are as the followings:

‐DISCUSSION (page 2626, left column, line 4)

In this subgroup analysis, anlotinib significantly improved PFS not only in ACC patients (5.5 months vs 1.4 months; HR: 0.23; 95% CI: 0.17–0.30) but also in SCC patients (4.8 months vs 2.7 months, HR: 0.43; 95% CI: 0.18–0.59). OS was improved significantly in ACC patients (9.6 months vs 6.9 months; HR: 0.68; 95% CI: 0.48–0.88), while it was prolonged without a statistically significant difference in SCC patients (10.7 months vs 6.5 months; HR: 0.75; 95% CI: 0.43–1.25).

The authors have miscalculated in Table 2 (SCC part) and also relevant values are revised in the section under Discussion. The correct version of Table 2 is displayed below:

Revised relevant values in the text are as the followings:

DISCUSSION (page 2628, left column, line 6)

In the ALTER0303 trial, hemoptysis occurred in 26.42% of SCC patients treated with anlotinib and the incidence of grade 3 or worse hemoptysis was 9.43%.

The authors have made changes in text for Figure 2A,B citation in text.

A figure number quoting mistake revised as the followings:

‐RESULTS 3.3 | Subgroup analysis in ACC and SCC (page 2624, right column)

In ACC patients, anlotinib significantly prolonged PFS in most subgroups (Figure 2B).

OS was significantly prolonged with anlotinib in patients with an EGFR mutation, an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 1, and >3 metastases and in patients who received two chemotherapy regimens or targeted regimens (Figure 2A).

The authors apologize for these errors.

REFERENCES

  • 1. Cheng Y, Han B, Li K, et al. Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med. 2020;9(8):2621–2630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Cheng Y, Han B, Li K, et al. Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med. 2020;9:2621–2630. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Medicine are provided here courtesy of Wiley

RESOURCES